10-Q: Liminatus Pharma Q1 2026 Financial Results

Liminatus Pharma reports a net loss of $1.12 million for Q1 2026 while highlighting ongoing efforts to regain Nasdaq compliance.

Summary

• Reported a net loss of $1.12 million for the three months ended March 31, 2026, compared to a net loss of $0.33 million in the same period of 2025.
• Operating expenses increased to $1.10 million, driven by $0.70 million in general and administrative costs and $0.40 million in research and development.
• Cash position improved to $1.91 million as of March 31, 2026, up from $0.34 million at year-end 2025, primarily due to a February 2026 public offering.
• Completed a public offering in February 2026, raising approximately $3.44 million in net proceeds.
• Total stockholders' deficit significantly reduced to $0.13 million from $9.81 million at the end of 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the 'going concern' warning, material weaknesses in internal controls, and ongoing Nasdaq delisting threats.

Positives

• Successful completion of a public offering in February 2026, providing $3.44 million in net proceeds to support operations.
• Significant reduction in total stockholders' deficit from $9.81 million to $0.13 million.
• Cash balance increased to $1.91 million, providing a temporary liquidity runway.

Negatives

• Net loss widened to $1.12 million compared to $0.33 million in the prior year period.
• Operating expenses rose by 317% year-over-year.
• Management identified material weaknesses in internal control over financial reporting, specifically regarding the control environment and segregation of duties.
• The company is currently not in compliance with certain Nasdaq listing rules regarding market value and minimum bid price.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Potential delisting from Nasdaq if compliance with market value and bid price rules is not regained by the prescribed deadlines.
• Heavy reliance on future equity or debt financing to fund ongoing operations.
• Uncertainty regarding the successful development and commercialization of the IBA101 product candidate.
• Potential dilution of existing shareholders through future capital raises.

Future Outlook

The company plans to raise additional capital through equity and debt financings to fund operations, though there is no assurance such capital will be available on acceptable terms. Management is working to regain compliance with Nasdaq listing rules.

Management Comments

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year after the date the financial statements are issued.
• The company is working diligently to regain compliance with Nasdaq's listing rules.

Industry Context

StockSavvy.ai notes that Liminatus Pharma is navigating the typical high-burn, high-risk environment of a pre-clinical biopharmaceutical company, exacerbated by the complexities of a recent SPAC business combination and ongoing Nasdaq compliance challenges.

Comparison to Industry Standards

• The company's reliance on related-party debt is common for early-stage biotech firms but presents governance risks.
• The use of pre-funded warrants and common stock warrants in the February 2026 offering is a standard mechanism for small-cap biotech companies to raise capital in a constrained market.

Corporate Governance

Legal Proceedings

• The company settled a legal action with Clear Street LLC in February 2026, involving the issuance of 4,000,000 shares of common stock.

Related Party Transactions

• Significant history of loans from related parties including Feelux Co., Ltd., Valetudo Therapeutics LLC, Ewon Comfortech Co., Ltd., Prophase Sciences LLC, Hana Immunotherapeutics, LLC, and Amantes LLC.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Creditors are impacted by the company's ongoing liquidity constraints and reliance on related-party debt deferrals.

Next Steps

• Regain compliance with Nasdaq listing rules regarding market value and bid price.
• Continue development of IBA101 candidate.
• Seek additional capital to fund operations.

Key Dates

Recommendation

The combination of a 'going concern' warning, material weaknesses in internal controls, and the threat of Nasdaq delisting makes this a highly speculative and risky investment, unsuitable for most institutional or conservative investors.

Keywords

Liminatus Pharma, Biopharmaceutical, CD47, Cancer Therapy, Nasdaq, Going Concern, IBA101